Quantcast

Latest Piperazines Stories

2014-02-12 08:28:26

- BL-8040 study published in Molecular Cancer Therapeutics - JERUSALEM, Feb. 12, 2014 /PRNewswire/ -- BioLineRx (NASDAQ: BLRX; TASE: BLRX), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, announced today positive pre-clinical results for BL-8040 in a third indication - as a treatment for chronic myeloid leukemia. Results of the study were recently published in Molecular Cancer Therapeutics. (Logo:...

2014-02-11 16:25:38

First liquid formulation clozapine for treatment-resistant schizophrenia DUBLIN, Feb. 11, 2014 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced U.S. commercial availability of Versacloz(TM) (clozapine, USP) oral suspension, the first and only oral suspension clozapine for severely ill treatment-resistant schizophrenia patients or those at risk of recurrent suicidal behavior with schizophrenia or schizoaffective disorder. "We are pleased to offer patients with...

2014-02-11 08:31:56

Agency Proposes Select Phase I Studies as Part of Resubmission RALEIGH, N.C., Feb. 11, 2014 /PRNewswire/ -- Sprout Pharmaceuticals announced today that their Formal Dispute Resolution, which was filed in December 2013, resulted in clear guidance from the FDA on the path forward. Sprout will resubmit the New Drug Application (NDA) for flibanserin, a once-daily treatment for Hypoactive Sexual Desire Disorder (HSDD) in premenopausal women, by the third quarter. The FDA has requested...

2014-02-05 12:28:03

Over 400 subjects participating in phase 3 studies PINE BROOK, N.J., Feb. 5, 2014 /PRNewswire/ -- Elusys Therapeutics, Inc. (Elusys), a biopharmaceutical company developing antibody therapies to treat infectious disease, today announced it has completed enrollment in three phase 3 safety studies of ETI-204, an anti-toxin in development for the treatment of inhalational anthrax. Elusys also announced it has completed enrollment in an additional study to evaluate the tolerability...

2014-01-30 08:29:44

AMSTERDAM, January 30, 2014 /PRNewswire/ -- Medical Brands has obtained a Class IIb status for it's Uninary Tract Infections Self-Care Medical Device Based upon latest test and study reports, authorities approved the class IIb status for the Urinary Tract Infections Self-Care Medical Device developed by Medical Brands. With this status it is possible to continuously use the product, exceeding 30 days, in order to prevent Urinary...

2014-01-16 12:31:27

EATONTOWN, N.J., Jan. 16, 2014 /PRNewswire/ -- Heritage Pharmaceuticals Inc. ("Heritage") announced the immediate availability of Prochlorperazine Edisylate Injection in the 5mg/mL strength. This product is the AP rated generic equivalent to the former brand Compazine and adds to Heritage's growing portfolio of generic injectable prescription products. According to IMS data for the twelve-months ended December 2013, the U.S. market for Prochlorperazine Edisylate Injection...

2014-01-09 08:28:38

LONDON, Jan. 9, 2014 /PRNewswire/ -- The Avillion Group (Avillion), a co-developer of late-stage clinical assets, announced today that it has entered into an exclusive collaborative development agreement with Pfizer Inc. to conduct a global Phase 3 clinical trial of Pfizer's BOSULIF(®) (bosutinib). The trial, which will be conducted across multiple sites in the United States, Asia and Europe, will evaluate BOSULIF, administered at a starting dose level of 400 mg daily, as a...

2014-01-08 17:34:19

Intravenous/sublingual tissue-penetrating homing peptide enhances activity of other pulmonary drugs, according to new research published in the American Journal of Pathology The development of new, more effective vasodilators to treat pulmonary arterial hypertension (PAH) has been hampered because of their systemic toxicity and adverse side effects. An international team of investigators seeking to surmount these problems and increase drug efficacy have determined that a vascular homing...

2014-01-08 12:28:08

Presentation to be held at Monday, January 13, 2014 at 10:00 a.m. Pacific Time at the Parc 55 Wyndam in Union Square, San Francisco TAMPA, Fla. and SAN DIEGO, Jan. 8, 2014 /PRNewswire/ -- HedgePath Pharmaceuticals, Inc. (OTCQB: HPPI), a clinical stage biopharmaceutical company that discovers, develops and plans to commercialize innovative therapeutics for patients with cancer, announced today that its president and chief executive officer, Mr. Nicholas J. Virca, will present at the...

2014-01-07 13:50:07

The cost of insurance co-payments for cutting-edge pharmaceuticals can vary widely from patient to patient. When the patient's share of prescription costs becomes too high, many patients skip doses or stop taking medication entirely, according to research conducted at the University of North Carolina. Using data from health plan claims for the anti-cancer drug imatinib filed between 2002 to 2011, Stacie B. Dusetzina, PhD, research professor at the UNC School of Medicine and Gillings School...


Word of the Day
barratry
  • The offense of persistently instigating lawsuits, typically groundless ones.
  • An unlawful breach of duty on the part of a ship's master or crew resulting in injury to the ship's owner.
  • Sale or purchase of positions in church or state.
This word ultimately comes from the Old French word 'barater,' to cheat.
Related